The WoVen Podcast
Canaan on Twitter
Canaan on LinkedIn
© Copyright 2022 Canaan |
Latest for Arvinas
Fierce Biotech: Biotech Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table
Pfizer is doubling down on Arvinas.
A milestone in targeted oncology and looking ahead
In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.
FierceBiotech: Arvinas eyes a busy 2021 as protein degraders gather steam in breast, prostate cancers
Arvinas’ lead protein degraders delivered promising early results in patients with hard-to-treat breast or prostate cancer.
FierceBiotech: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer
Arvinas has released promising first-in-human data for its protein degrader in prostate cancer.
Wired: These protein picker-uppers keep your cells clean and healthy
When it comes to tapping protein degraders to fight diseases like cancer, many assumed the biology worked, but the chemistry was no good. Arvinas...
Endpoints News: Pfizer bets $1B cash on the original protein degraders as technology nears prime time
BioCentury: Beyond PROTACs and the proteasome - broadening the TAC toolbox
Nature Reviews: First targeted protein degrader, developed by Arvinas, hits the clinic
Endpoints News: Bayer enlists Arvinas on two-pronged protein degradation effort, foraying into agtech
Arvinas has inked another Big Pharma partnership to get their protein degradation engines revving — for both humans and crops.
Business Insider: Scientists are working on cancer treatments that attack the disease's 'Holy Grail"
PROTAC technology brings "unlimited" possibilities for cancer treatment says Arvinas founder & CSO Craig Crews. "It can be applied to so many...
Nature: Protein-slaying drugs could be the next blockbuster therapies
Researchers at Arvinas are hijacking the cell’s protein-disposal system in the fight against Alzheimer’s and intractable cancers.
Nasdaq: Cancer biotech Arvinas prices upsized IPO at $16
Arvinas, a preclinical biotech developing protein degradation therapies for advanced cancers, raised $120 million by offering 7.5 million shares at...
Scientific American: New thalidomide-like therapy hijacks cells’ trash-disposal system